Search Orphan Drug Designations and Approvals
-
Generic Name: | imatinib mesylate | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Trade Name: | Gleevec | ||||||||||||||||
Date Designated: | 12/19/2005 | ||||||||||||||||
Orphan Designation: | Treatment of dermatofibrosarcoma protuberans | ||||||||||||||||
Orphan Designation Status: | Designated/Approved | ||||||||||||||||
Sponsor: |
Novartis Pharmaceuticals Corporation One Health Plaza Mail Code 105/1E870D East Hanover, New Jersey 07936 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
||||||||||||||||
Marketing approved: |
|||||||||||||||||
1 | Generic Name: | imatinib mesylate |
---|---|---|
Trade Name: | Gleevec | |
Marketing Approval Date: | 10/19/2006 | |
Approved Labeled Indication: | Treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP) | |
Exclusivity End Date: | 10/19/2013 | |
Exclusivity Protected Indication* : | ||
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-